Porton Advanced, Royaltech Establish Bacterial and mRNA Drugs Agreement


Collaboration expected to accelerate the bionnovative drug R&D process

Porton Advanced Solutions, a cell and gene therapy (CGT) contract development and manufacturing organization (CDMO), is partnering up with Suzhou Royaltech Med Co., Ltd., who focuses on the development of vaccines for tumor immunotherapy with its proprietary technologies.

This strategic collaboration—the companies say—will further integrate the resources and capabilities of both parties, jointly promote the establishment of microbial vectors used for gene therapy (MVGTs) (listeria monocytogenes) and mRNA drug platform technology, and speed up the R&D process of bioinnovative drugs.

"We are very pleased to enter into this strategic collaboration with Royaltech,” notes Dr. Yangzhou Wang, CEO of Porton Advanced. “The core management team of Royaltech is from the top pharmaceutical companies, with an average of 15 years of R&D and management experience, and is advancing an internationally competitive R&D pipeline. Porton Advanced's end-to-end gene and cell therapy CDMO platform, with rich project experience and comprehensive-quality system, will help Royaltech [with] the development of Listeria and mRNA drugs, push its R&D pipeline in a quick, efficient manner, and accelerate the development and implementation of innovative drugs, so that good medicines can benefit the public earlier."

Related Videos
© 2024 MJH Life Sciences

All rights reserved.